Regeneron says half its COVID-19 treatment doses are being sent to 4 low-vaccination states

Regeneron infusion center in Florida
(Image credit: Chandan Khanna/AFP/Getty Images)

Health officials agree that if you are newly infected with COVID-19 and have an above-average risk of getting seriously ill, you should quickly seek treatment with Regeneron Pharmaceuticals' monoclonal antibody therapy. The federal government is covering the costs, some states have set up free infusion centers, and the antibody cocktail has been shown to reduce hospitalization rates by 70 percent for high-risk COVID-19 patients treated within 10 days.

"They are safe, they are free, they keep people out of the hospital and help keep them alive," Dr. Marcella Nunez-Smith, a senior adviser to the White House's COVID-19 response team, said at an Aug. 12 White House briefing.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.